Primary testicular lymphoma

• Published in: Swiss medical weekly Vol. 140; no. 3738; p. w13076
• Main Authors: Zouhair, A, Herrmann, E, Ugurluer, G, Gaye, P M, Mirimanoff, R O, Ozsahin, M
• Format: Journal Article
• Language: English
• Published: Switzerland SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2010
• Subjects: Aged; Brain Neoplasms - prevention & control; Brain Neoplasms - secondary; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Humans; Lymphatic Irradiation; lymphoma; Lymphoma, Non-Hodgkin - drug therapy; Lymphoma, Non-Hodgkin - pathology; Lymphoma, Non-Hodgkin - radiotherapy; Lymphoma, Non-Hodgkin - surgery; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Testicular Neoplasms - drug therapy; Testicular Neoplasms - pathology; Testicular Neoplasms - radiotherapy; Testicular Neoplasms - surgery; testis; Treatment
• ISSN: 1424-7860; 1424-3997
• DOI: 10.4414/smw.2010.13076

Primary testicular lymphoma (PTL) is a rare disease accounting for 1% of non-Hodgkin's lymphoma. PTL occurs more frequently in older patients and is a potentially fatal disease. In the early stages (I and II), the treatment consists of orchidectomy followed by chemotherapy (CT) and prophylactic scrotal radiotherapy (RT) with/or without iliac and/or paraaortic lymph node RT. In the advanced stages (III and IV), CT is the treatment of choice whereas the place of scrotal RT is controverted. In both early and advanced disease intrathecal CT is warranted to prevent CNS relapse. New molecular approaches and/or more aggressive treatments are being explored.